Comparative analysis of carbomer polymers for pharmaceutical and cosmetic practice
DOI:
https://doi.org/10.14739/2310-1210.2020.3.204960Keywords:
carbomers, carbopols, carbomer homopolymer, carbomer interpolymer, carbomer copolymer, carboxyvinyl polymerAbstract
The aim of the study. Given the wide range of carbomers, their manufacturing technologies, solvent systems for their synthesis, differences in name and regulation, there is a need to systematize this group of excipients for the pharmaceutical and cosmetic industries. When using carbomers in the pharmaceutical development of medicines, the results of additional studies on the compliance of quality with pharmacopoeial indicators should be provided in registration materials.
Materials and methods. As materials used were data from the official websites of the Ministry of Health of Ukraine, the FDA and Lubrizol; Pharmacopoeias of the United States (USP/NF), Europe (Ph. Eur) and Japan (JPE); scientific publications. Methods of information retrieval, systematization of theoretical and practical material were used.
Results. As a result of studying the official regulatory documents it has been found that the US Pharmacopoeia (USP/NF) contains monographs called “Carbomer Copolymer”, “Carbomer Interpolymer” and “Carbomer Homopolymer”, which are classified into types A, B, C for polymers synthesized without the use of benzene, and monographs “Carbomer934”, “Carbomer 934Р”, “Carbomer940”, “Carbomer941”, “Carbomer1342” – for polymers synthesized using benzene. The Pharmacopoeia of Europe (Ph. Eur) contains a monograph “Carbomers” of a general nature, the requirements of which are met only in “Carbomer Homopolymer” polymers synthesized without the use of benzene by USP/NF. The Japan Pharmacopoeia (JPE) contains the monograph “Carboxyvinyl Polymer”, which includes carbomers synthesized both with and without benzene.
Conclusions. The USP/NF pharmacopoeial quality requirements are met in the trademarks of carbomers: Carbopol 71G NF, Carbopol 971P NF, Carbopol 974P NF, Carbopol 980 NF, Carbopol 981 NF, Carbopol 5984 EP, Carbopol 934 NF, Carbopol 934P NF, Carbopol 940 NF, Carbopol 941 NF, Carbopol 1342 NF, Carbopol Ultrez 10 NF, Carbopol ETD 2020 NF, Pemulen TR-1 NF, Pemulen TR-2 NF, Noveon AA-1 USP. Only 6 brands of carbomers meet the requirements of the European Pharmacopoeia: Carbopol 71G NF, Carbopol 971P NF, Carbopol 974P NF, Carbopol 980 NF, Carbopol 981 NF, Carbopol 5984 EP.
References
(2013). Lubrizol. Compendial Specifications. Applicable to Pharmaceutical Polymers. Lubrizol Advanced Materials, Inc. https://docplayer.net/89257600-Compendial-specifications.html
Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). (2013). Carbomers. European Pharmacopoeia (8th ed., Vol. 2, pp. 1766-1768). Council of Europe.
Center for Drug Evaluation and Research, Office of Pharmaceutical Quality & Office of Policy for Pharmaceutical Quality. (2020, January 30). Inactive Ingredient Search for Approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
Lubrizol. (2011, May 31). Formulating Semisolid Products. Pharmaceutical Bulletin, (21), 1-7.
Sheskey, P. J., Cook, W. G., & Cable, C. G. (Eds.). (2017). Handbook of Pharmaceutical Excipients (8th ed.). American Pharmacists Association, Pharmaceutical Press.
Lubrizol. (n.d.). Product Finder. 28 product found. Lubrizol Beauty & Personal Care. https://www.lubrizol.com/Personal-Care/Products/Product-Finder
Lubrizol. (n.d.). Global Regulatory Status. Lubrizol Pharmaceuticals. https://www.lubrizol.com/Health/Pharmaceuticals/Regulatory/Global-Regulatory-Status
Lubrizol. (n.d.). Carbopol® Polymers. Lubrizol. https://www.lubrizol.com/Home-Care/Products/Carbopol-Polymers
Lubrizol LifeSciences. (2017, July). Pharmaceutical Excipients Guide. Lubrizol LifeSciences. Lubrizol Advanced Materials, Inc.
Lubrizol. (2013, October). Pharmaceutical Polymers Typical Properties and Specifications. Lubrizol Advanced Materials, Inc.
Lubrizol. (2011, May 31). Polymers for Pharmaceutical Application. Pharmaceutical Bulletin, (1), 1-9.
Lubrizol. (2011, May 31). Toxicology Studies and Regulatory Information Pharmaceutical Bulletin, (2), 1-17.
United States Pharmacopeial Convention. (2009). USP 32 NF 27: United States pharmacopeia [and] national formulary. Supplement 1. United States Pharmacopeial Convention. https://www.uspnf.com/official-text/proposal-statuscommentary/usp-32-nf-27
Ministry of Health of Ukraine (n.d.). Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State Register of Medicines of Ukraine]. http://www.drlz.kiev.ua
Ministry of Health of Ukraine. (2003, January 15). Pro zatverdzhennia perelikiv dopomizhnykh rechovyn ta barvnykiv, dozvolenykh dlia zastosuvannia u vyrobnytstvi likarskykh zasobiv, shcho (likarski zasoby) reiestruiutsia v Ukraini ta vyhotovliaiutsia v aptechnykh umovakh za retseptamy likariv i zamovlenniamy likuvalno-profilaktychnykh zakladiv [On approval of lists of auxiliary substances and dyes authorized for use in the manufacture of medicinal products that (medicines) are registered in Ukraine and are made in pharmacy conditions on prescriptions of doctors and orders of medical and preventive establishments (No. 8)]. https://zakon.rada.gov.ua/laws/show/z0069-03
Gladukh, Ye. V., Grubnik, І. М., & Kukhtenko, Н. Р. (2017). Vliyanie solyubilizatora PEG-40 gidrogenizirovannoe kastorovoe maslo na strukturno-mekhanicheskie svoistva gelei karbopola [Influence of solubilizer PEG-40 hydrogenated castor oil on carbopol gels’ structural-mechanical properties]. Current issues in pharmacy and medicine: science and practice, 10(3), 288-295. https://doi.org/10.14739/2409-2932.2017.3.113552 [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)